<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

Patrick Brennan

LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Posts by Patrick Brennan

Eyeing up the global aesthetics market

Here are some lessons we learned during a recent interview with CFO Alan Ol...

Read More

10 things we learned from Medicines Discovery Cata...

With a strong focus on the collaboration needed to solve problems common to...

Read More

Of Mice and Men: Kymab scurries up the biologics l...

Using the pioneering Kymouse human antibody expression platform, Kymab are ...

Read More

Cancer’s Achilles heel has been found

In March of this year, an article published in Science made waves throughou...

Read More

Equity Crowdfunding and life sciences

Equity crowdfunding is particulary suited to life sciences

Read More

How does equity investment work?

What is equity crowdfunding? To any average member of Joe public, the word ...

Read More

Maxcyte: Aiming to be the very best in cell therap...

Having recently listed on the London Stock Exchange, CEO Doug Doerfler tell...

Read More

8 Things we learned from Orphan Drugs Industry Adv...

Christian Girard, expert in orphan drugs, competitive intelligence, in/out ...

Read More

Collaborations in novel, highly potent drug classe...

Biotech and Money had the opportunity to speak with Alastair Smith, the CEO...

Read More

Top 4 Tips you need to prepare for Biotech IPO

Biotech companies have fared well recently in the IPO market in both the US...

Read More

9 things we learned from F2G CEO Ian Nicholson

Ian has over 25 years of international experience in management and transac...

Read More

Mironid: Giving off all the right signals

Comprising a team with expertise in both development and commercialisation,...

Read More

Add Your Response